Validation of the MAGIC genomic signature on RNAseq in soft-tissue sarcomas

Ataaillah Benhaddou[1,6], Gaëlle Pérot[1,2], Philippe Rochaix[1,3], Thibaud Valentin[1,4], Gwenaël Ferron[1,5], Frédéric Chibon[1, 3*]

(1) OncoSarc, INSERM U1037, Cancer Research Center in Toulouse (CRCT), 31000, Toulouse, France.

(2) Centre Hospitalier Universitaire (CHU) de Toulouse, IUCT-Oncopole, 31000, Toulouse, France.

(3) Department of Pathology, Oncopole Claudius Régaud, IUCT-Oncopole, 31000, Toulouse, France.

(4) Department of Oncology, Oncopole Claudius Régaud, IUCT-Oncopole, 31000, Toulouse, France.

(5) Department of Surgical Oncology, Institut Claudius Régaud, IUCT-Oncopole, 31000, Toulouse, France.

(6) Magic Genomix, 13, rue saint Ursule, 31000, Toulouse, France.

* Corresponding author

Abstract

(1) Background: Genomic Instability (GIN) plays a critical role in cancer progression and treatment response. Soft tissue sarcomas (STS), are characterized by high levels of chromosomal rearrangements and transcription-associated stress, both of which contribute to poor clinical outcomes. Current standard grading systems, such as FNCLCC, are limited in prognostic accuracy for STS, necessitating novel approaches for risk stratification and treatment guidance. To address this gap, we developed a holistic classifier, the MAGIC (Mixed transcription- and replication-associated GIN classifier), combining transcription- and replication-related GIN indices (iTRAC and iRACIN) to predict metastatic risk.

(2) Patients and Methods: This study utilized RNA sequencing (RNAseq) on 226 STS tumor samples to analyze fusions transcript's break points (BP) distribution and assess GIN. We computed MAGIC indices iTRAC and iRACIN, which are based on chromosomal instability linked to transcription and replication processes, respectively. iTRAC biomarker was evaluated against FNCLCC and CINSARC for metastatic risk stratification. Kaplan-Meier and iPART analyses were used to determine the prognostic relevance of iTRAC levels.

(3) Results: iTRAC significantly stratified patients with distinct metastatic outcomes, outperforming FNCLCC and CINSARC grading systems. STS patients with medium level of iTRAC showed the poorest metastasis-free survival. Patients classified as iTRAC high- and low-risk groups, achieved better prognosis. Furthermore, iTRAC stratified patients' metastatic risk in treated and not treated patients, indicating poorer prognosis with chemotherapy in patients with low iTRAC and better for those with with medium iTRAC.

(4) Conclusion(s): iTRAC demonstrates a superior prognostic utility in STS over current grading systems, effectively stratifying metastatic risk for patients who might benefit from alternative therapeutic strategies. iTRAC holds potential for personalizing chemotherapeutic approaches, paving the way for a new precision oncology approach in STS.

Introduction

The non-linear relationship between GIN and clinical outcome is a recent and paradigm shifting concept in genomics and cancer therapeutics (Birkbak *et al*. 2011; Roylance *et al*. 2011; Andor *et al*. 2016; Benhaddou *et al*. 2021;). Several cancers were reported to show a non-linear relationship between GIN and clinical outcome comprising breast, ovarian, gastric, non–small cell lung cancers and leiomyosarcomas (Birkbak *et al*. 2011; Roylance *et al.* 2011; Benhaddou *et al*. 2021). This may have important implications for patient's risk stratification and therapeutic choice. Interestingly, this non-linear relationship between GIN and prognosis has been proposed as the underlying mechanism why some gene expression approaches which are also correlated with GIN, such as Oncotype DX and MammaPrint, have limited prognostic value in ER-negative breast cancer (Roylance *et al*. 2011; Birkbak *et al*. 2011). Development of diagnostic methods that take into account this non-linear relationship between GIN and clinical outcome is therefore of paramount importance to leverage more efficiently cancer genomics for clinical care.

GIN is associated with poor prognosis in solid tumors (Carter *et al*. 2006; Walther, Houlston and Tomlinson 2008; Chibon *et al*. 2010) and the rate of aneuploidy and karyotypic abnormalities increases with tumor grade and invasiveness (Walther, Houlston, and Tomlinson 2008; Yamamoto *et al*. 2007; Florl and Schulz 2008; M'kacher *et al*. 2010; Florl and Schulz 2008). Conversely, experimental data show that chromosome missegregation and aneuploidy can also inhibit tumorigenesis (Weaver and Cleveland 2008). This is because aneuploidy may also cause proliferative disadvantage (Williams *et al*. 2008). Consequently, aneuploidy may have both tumor promoting and tumor suppressive effects in animal model systems (Schvartzman, Sotillo and Benezra 2010; Baker *et al*. 2009). Such a paradoxical relationship between GIN and clinical outcome suggests that there may have an optimal level of GIN for tumor progression, beyond which further instability generates non-viable karyotypes and provides no growth advantage that may even be deleterious for cancer cell fitness and aggressiveness (Cahill *et al*. 1999). Computational work corroborates this idea and predicts that a chromosome missegregation rate between 10^{-3} and 10^{-2} per chromosome is optimal for cellular fitness (Komarova and Wodarz 2004). The same idea was proposed for mutation rates for the fitness of population in dynamic environment (Nilsson *et al*. 2002).

MAGIC is a genomic signature, composed of two biomarkers and an algorithm which explores the relationship between GIN and clinical outcomes, which was first developed on whole genome sequencing (WGS) of leiomyosarcomas (Benhaddou *et al*. 2021). MAGIC employs a random breakage model to assess the enrichment of BP in selected structural and/or functional genomic sequences. It consists of two biomarkers that measure the concentration of DNA BP associated with transcription (iTRAC) and replication (iRACIN). Using MAGIC approach, we have shown that a medium level of iTRAC and iRACIN is associated with poor clinical outcome compared to low and high levels. We have also shown that in iTRAC-Low patients group, patients treated with chemotherapy have increased metastatic risk compared to not-treated patients. No statistically significant difference between chemotherapy treated and not treated patients has been observed in iTRAC-Medium and High groups.

MAGIC has implications in precision oncology but WGS is not currently the first choice in routine clinic. We therefore sought to translate MAGIC on RNAseq, a widely used technique in the clinics because it is cheaper and allows gene expression quantification for functional analysis of genes expression programs for multiple diagnostic and R&D purposes. To do so, we used the same cohort of leiomyosarcomas published in Benhaddou *et al*. 2021 and a second independent cohort previously published by our team (Lesluyes *et al*. 2016) of pleomorphic soft-tissue sarcomas for which RNAseq data were available. We combined the two cohorts into one single Pan-soft tissue sarcoma cohort (PanSTS) of 226 patients (Supplementary table 1 and supplementary table 2) and reanalysed RNAseq data to detect BP.

Methods

RNAseq data

The RNA-seq data utilized in this study were sourced from studies previously published by our team: 1) Darbo *et al*. 2023 and 2) Lesluyes *et al*. 2016 which can be downloaded from the following links: https://ega-archive.org/studies/EGAS00001001262 and https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71119 respectively.

Bioinformatics analysis pipeline for RNA-seq

We estimated general read quality using FastQC (v0.10.1), trimmed low-quality 5' and 3' ends (Phred score <20) using TrimGalore (https://github.com/FelixKrueger/TrimGalore). Transcriptomic (coding RefSeq genes from Hg38 UCSC Table Browser (Kuhn, Haussler, et Kent 2013) fixed on 2021/03/18) alignments were performed by STAR (v2.6.0c) (Dobin *et al*. 2013). Once aligned, we removed paired-end reads that mapped at multiple locations on transcriptome, low-quality (score <20) and discordant paired-end reads using SAMtools (v0.1.19)(Li *et a*l. 2009). MarkDuplicates (PicardTools v1.99 “Picard Toolkit.” 2018. Broad Institute, GitHub Repository. http://broadinstitute.github.io/picard/; Broad Institute) removed PCR duplicates and Cufflinks (v2.1.1) (Trapnell *et al*. 2012) estimated gene and transcript abundances. HTSeq (v0.5.4) (Anders, Pyl, et Huber 2015) numbered reads mapped to Spike-in and reference chromosomes. We used Arriba (Uhrig *et al*. 2021), for the detection of fusion transcripts from RNA-Seq data with defaults parameters.

Statistical analysis.

All statistical tests were carried out using R version 4.1.2 (2021-11-01);R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria;http://www.r-project.org/index.html). Kaplan-Meier method was used for survival curves construction. Log-rank test was used to compare survival curves between groups. Cox regression was used for multivariate analysis.

iPART, iTRAC, iRACIN, BP count

iPART is the stratification algorithm used to split cohort into groups of different levels of iTRAC and iRACIN and was applied as published in Benhaddou *et al*. 2021. iTRAC and iRACIN biomarkers were computed as described in Benhaddou *et al*. 2021. Total BP count for each patient was computed as the sum of split read coverage of all BP in each patient. Similarly, BP count for each iTRAC and iRACIN biomarkers was computed as the sum of split read coverage of each BP present in each biomarker. Here how it is done:

The readable genome is represented as a single interval of length L in base pairs (bp). The uniform probability Pu of any genomic position to carry a BP is computed as:

$$Pu = \frac{n}{L}$$

where:

- n is the total number of BP, now computed as the sum of split read coverages over all BP,
- L=2,948,611,470 bp is the total readable genome size (total ungapped genome length from NCBI assembly GCF_000001405.26).

For a given genomic interval of size Li and ni BP, the probability of harboring ni BP under the random breakage model (RBM) is computed using the binomial probability mass function:

$$P(X = n_i) = \binom{L_i}{n_i} P_u^{n_i} (1 - P_u)^{L_i - n_i}$$

where:

- X is the random variable representing the number of BP in the interval,
- n_i is the **total BP count** in the interval (sum of split read coverages over all BP in the interval),
- L_i is the **size of the interval** (sum of merged interval sizes),
- P_u is the **uniform probability of BP occurrence**.

The probability of observing **more than n_i BP** under RBM is:

$$P(X > n_i) = 1 - P(X \leq n_i) = 1 - \sum_{x=0}^{n_i} P(X = x)$$

The **H-score** is then computed as:

$$H = -\log_{10} P(X > n_i)$$

Results

Medium level of iTRAC measured on fusion transcripts BP is associated with poor clinical outcome.

Using WGS we previously showed that medium levels of iTRAC and iRACIN are predictive of poor clinical outcome (Benhaddou *et al*. 2021). We therefore sought to check whether this observation still holds using RNAseq. We computed Hscore for iTRAC and iRACIN on the total of the fusion transcripts BP identified in the whole panSTS cohort (226 patients). We found that for iTRAC in the whole cohort, an Hscore equal to 350 (expected BP count = 21028, observed BP count =41148) meaning that fusion transcripts BP are highly overrepresented in iTRAC DNA elements compared to what is expected by chance. Fusion transcripts BP was depleted in iRACIN, with an Hscore equal to 0 (expected BP count =32654 , observed BP count =3943). Indeed iRACIN DNA elements are more associated with replication related GIN. Therefore, it is only iTRAC that is relevant as a biomarker applied to the transcriptome of this data set. We then computed iTRAC for each individual patient and applied the iPART algorithm (Benhaddou *et al*. 2021) to split the patients of PanSTS cohort which did not receive chemotherapy (167 patients) into 3 groups of distinct levels of iTRAC: Low, Medium and High. Kaplan-Meier analysis shows that application of iTRAC over RNAseq fusion transcripts BP significantly stratified the untreated (*i.e*. without chemotherapy) panSTS cohort ($P< 0.0001$) into three groups with nonlinear relationship between iTRAC Hscore and clinical outcome (MFS) (fig 1A). Concordantly with results obtained with WGS, it is the group of patients with medium iTRAC that has the most unfavorable outcome compared to the reference group (Low iTRAC) with hazard ratio (HR) of 5 ($P=1.57x10^{-8}$) (fig 1B). We also confirmed that Low and High iTRAC have similar clinical outcome (HR=1, $P=4.28x10^{-1}$) (fig 1B).

Chemotherapy is associated with a decreased MFS in Low iTRAC patients and an increased MFS in Medium iTRAC Patients

Using WGS and leimoyosarcoma cohort, we have previously shown that in Low iTRAC group, patients treated with chemotherapy have increased metastatic risk compared to patients not treated (Benhaddou *et al*. 2021). To check whether this observation holds in panSTS cohort using

RNAseq, we split panSTS patients having chemotherapy (59 patients) into Low, Medium and High levels using the thresholds determined with patients not treated with chemotherapy. First we observed that the prognostic value of iTRAC stratification (Low, Medium and High) changed significantly (fig 1C) with the poorer MFS for the Low iTRAC group (HR = 4.95; P = 2.22x10-3; fig 1D), the better for the High iTRAC group and an intermediate MFS for the Medium group. Thus, we analyzed separately each iTRAC group. In Low iTRAC group, patients who received chemotherapy have a higher metastatic risk than those who did not (fig 1E). Interestingly, in the Medium iTRAC group, patients who received chemotherapy have a better MFS (fig 1F, HR=3.01, P = 3.33 10-2). Finally, no significant difference in MFS was observed between patients with or without chemotherapy in High iTRAC (fig 1G). Therefore, Low and Medium levels of iTRAC for patients treated with chemotherapy are associated with different MFS contrary to patients not treated with chemotherapy. Taken together, these results show that Low iTRAC patients treated with chemotherapy have a poorer prognosis whereas Medium iTRAC patients treated with chemotherapy have a better prognosis than those not treated with chemotherapy.

iTRAC performs better than FNCLCC and CINSARC in stratifying metastatic risk in panSTS cohort.

The current standard in sarcomas for predicting patient evolution is the histological FNCLCC grading system (Coindre *et al*. 2001). Complexity INdex in SARComa (CINSARC), which is the main expression-based prognostic signature of sarcomas, is currently under prospective clinical investigation for patients stratification (Chibon *et al*. 2010; Filleron *et al*. 2020). FNCLCC grading did not significantly split the panSTS cohort into groups with different metastatic evolution for both chemotherapy-treated and not treated patients (fig 2A and 2B). Interestingly, for CINSARC, while there is a significant difference in MFS between groups C1 and C2 for patients without chemotherapy, there is no statistically different MFS between C1 and C2 for patients with chemotherapy (fig 2C and 2D). Consequently, no significant difference in MFS between patients treated or not by chemotherapy was observed in each group of FNCLCC grade and CINSARC (fig 3A, 3C, and fig 3B, 3D). Multivariate analysis with a Cox proportional hazard model comparing iTRAC, CINSARC and FNCLCC grading shows (fig 4) that in patients who did not receive

chemotherapy, Medium iTRAC is significantly associated (P<0.001) with increased HR of metastatic risk but not FNCLCC nor CINSARC (fig 4A). Conversely, in chemotherapy-treated patients, Low iTRAC, but not FNCLCC or CINSARC, was significantly associated with increased metastatic risk compared to High iTRAC, while the Medium iTRAC group was no longer significantly associated with increased MFS (fig 4B). Taken together, these results show that iTRAC outperforms both FNCLCC grading system and CINSARC signature in stratifying metastatic risk both in chemotherapy treated and not treated patients.

Discussion

Medium levels of iTRAC measured on RNAseq is associated with poor prognosis

We have previously shown that Medium level of iTRAC in LMS, measured on WGS, is associated with poorer clinical outcome than High and Low levels (Benhaddou *et al*. 2021). Here we established the same conclusion by measuring iTRAC by RNAseq in a cohort of 226 pleomorphic STS. This finding opens the door to a wide prospective clinical evaluation of MAGIC in the clinic for these pleomorphic sarcomas and other cancers for which the non-linear relationship between GIN and clinical outcome was described, as for in ER^- breast cancers, lung, ovarian and gastric cancers (Roylance *et al*. 2011; Birkbak *et al*. 2011).

Medium level of iTRAC patients have a better prognosis in treated than in non-treated patients.

Our findings reveal that STS patients with Medium iTRAC exhibit distinct prognosis based on whether they received chemotherapy treatment or not. This observation adds a novel dimension to our understanding of the interplay between GIN and chemotherapy efficacy.

Previous studies have established a link between GIN and poor prognosis in solid tumors (Carter *et al*. 2006; Walther, Houlston and Tomlinson 2008; Birkbak *et al*. 2011). However, there is compelling evidence suggesting that certain cancer treatments, which induce GIN, may be more effective in cells with a higher baseline rate of aneuploidy. For instance, it has been shown that the

efficacy of treatments like Paclitaxel and radiation therapy improves under higher levels of GIN (Bakhoum *et al*. 2015), (Janssen, Kops, et Medema 2009), and (Zasadil *et al*. 2014). Similarly, rectal adenocarcinoma patients with elevated pre-treatment aneuploidy are more likely to respond positively to chemoradiation therapy (Zaki *et al*. 2014).

Several chemotherapeutic drugs have been shown to induce GIN *in vitro*, leading to additional structural variations (SVs) that surpass a threshold incompatible with cell survival (Andor *et al*. 2016; Kim *et al*. 2016; Bakhoum *et al*. 2015). This mechanism may underpin the improved prognosis observed in treated patients with medium iTRAC, suggesting that these treatments leverage the existing GIN to drive cancer cells beyond survivable limits.

Interestingly, Cahill and colleagues proposed that there is a need for an optimal level of GIN for tumor aggressiveness. Beyond this optimal level, additional instability generates non-viable karyotypes and provides no competitive advantage to cancer cells (Cahill *et al*. 1999). This concept is crucial for understanding why patients with medium levels of iTRAC likely benefit the most from chemotherapy.

In contrast, untreated patients with medium iTRAC might experience the detrimental effects of medium levels GIN without the benefit of systemic therapeutic intervention, resulting in a poorer prognosis. This dichotomy underscores the importance of treatment in managing medium level GIN and highlights the potential for personalized therapeutic strategies based on iTRAC levels. Our results, therefore, provide new insights supporting the notion that GIN, while generally associated with poor outcomes, can be exploited therapeutically to improve patient prognosis in specific contexts.

High level of iTRAC is not associated with a different MFS in treated or not treated patients.

Our findings indicate that high level of iTRAC is not associated with a significant difference in metastasis-free survival (MFS) between patients treated with chemotherapy and those who were not. This result aligns with previous research on GIN and cancer outcomes.

Cahill and colleagues (Cahill *et al*. 1999) proposed that GIN contributes to oncogenesis only up to a certain threshold. Beyond this threshold, the level of instability is likely to produce cells with unviable karyotypes, which are not sustainable for tumor progression. This concept is also crucial

in understanding why high levels of iTRAC do not confer additional survival benefits in the context of chemotherapy. In fact, when GIN surpasses a certain point, it may result in excessive cellular dysfunction, to which cancer cells became resistant by negative pressure selection, rendering further therapeutic interventions less effective.

The lack of prognostic difference in High iTRAC patients treated vs untreated is in line with what was reported by Birkbak and colleagues showing that the improved outcomes observed in tumors with very high aneuploidy appear to be independent of treatment (Birkbak *et al*. 2011). This suggests that once a high level of GIN is reached, the biological behavior of the tumor is driven more by the intrinsic instability rather than the effects of chemotherapy.

Low level of iTRAC is associated with an increase in MFS for patients treated with chemotherapy

Chemotherapy increases survival in patients in several cancers (Von Minckwitz *et al*. 2012; Rossi *et al*. 2015) but still remains controversial in STS. There are many patients who do not benefit from chemotherapy and few studies report that in some cases it might participate to metastatic relapse (Karagiannis, Condeelis, et Oktay 2018) by inducing cytokines (Daenen *et al*. 2014) and proinflammatory circuits (Byrd-Leifer *et al*. 2001). Interestingly, Low GIN cancer cells contain mainly stable genome (Birkbak *et al*. 2011). Thus they are the closest to a normal cell and this may explain at least in part their good prognosis. This may also be the case for Low iTRAC patients. The fact that in Low iTRAC group, patients having chemotherapy have decreased MFS compared to patients not treated, may be due to a global increase of GIN so that they become of medium level which is associated with more aggressive phenotype, either by inducing individual chromosomal instability or by targeting preferentially less rearranged and fast proliferating cells in an heterogenous cellular population.

Our findings highlight the nuanced role of GIN in cancer treatment outcomes. Low iTRAC levels are associated with increased MFS in untreated patients, while Medium iTRAC patients benefit from chemotherapy, suggesting an optimal window of instability for therapeutic exploitation. In contrast, high iTRAC levels do not show significant treatment benefits, likely due to the deleterious

effects of resistance of cancer cells to excessive additional GIN on cancer cells fitness. These insights underscore the importance of personalized therapeutic strategies that consider a patient's specific GIN profile to maximize treatment efficacy and improve prognosis.

Several confounding factors, like tumor grade and histotype, may undermine this hypothesis. We can't rule out the possibility that distinct prognosis in treated and non-treated patients could also be due to bias in patients selection inherent to retrospective studies. Therefore, it is only a controlled prospective analysis that will give the final answer to this question. Finally, we do not exclude the possibility that the Low iTRAC patients have different immune infiltrate than Medium or High ones and which portends them to be of higher risk of metastasis upon chemotherapy. Further controlled prospective studies are needed to explore the relationship between the different levels of iTRAC, immune infiltrate/tumor microenvironnement and chemotherapeutic response.

MAGIC, from whole genome to RNAseq

MAGIC was originally developed using BP of structural variations (SVs) identified through Whole Genome Sequencing, including insertions, deletions and translocations. Both iTRAC and iRACIN significantly stratified patients and demonstrated a non-linear relationship with clinical outcomes (Benhaddou *et al*. 2021). Notably, only iTRAC showed relevance in stratifying metastatic risk for chemotherapy treated and non-treated patients. Here, we applied MAGIC to RNA sequencing data using BP of fusion transcripts. Fusion transcripts arise from various events such as insertions, deletions and translocations (Aguilera et Gómez-González 2008). Notably, only iTRAC was measurable in RNA-seq data underscoring its unique capability to capture transcription-associated GIN. Therefore, the application of iTRAC to RNA-seq data effectively captures the complexity and relevance of transcription-associated GIN measured through WGS. This specificity makes iTRAC particularly relevant for identifying functionally significant genomic regions that directly impact gene expression and tumor behavior, providing valuable prognostic and therapeutic insights. Furthermore, fusion transcripts have prognostic relevance. For example, in breast cancer, associations have been reported between the number of fusion transcripts, copy number events, gene expression profiles and clinical outcomes (Thompson *et al*. 2016). Additionally, high

frequencies of fusion transcripts detected in breast cancer patients correlate with poor outcomes (Ma *et al*. 2014).

In summary, MAGIC's adaptation for RNA sequencing within the iTRAC biomarker distills the broader concept of GIN into a focused analysis of fusion transcripts. This approach enhances our ability to infer transcription-associated GIN and its implication for cancer prognosis and treatment strategies.

From quantity to enrichment: iTRAC and the qualitative dimension of genomic instability

A key nuance in the interpretation of Hscore lies in distinguishing between quantitative measures of genomic instability and qualitative enrichment in specific genomic regions. While the total number of BP reflects the overall burden of structural variations, Hscore captures the localized "hotspotness" of BPs, providing insights into the mechanistic underpinnings of GIN. Interestingly, using iPART, stratification of panSTS cohort by total BP counts is less effective than by number of BP in iTRAC (supplementary figure 1), further stressing the importance of regional context in genomic instability. This suggests that not all BP contribute equally to tumor behavior or treatment response. Those occurring within iTRAC-defined regions may reflect functionally relevant alterations, such as replication stress or fragile site collapse, thereby offering superior predictive and prognostic values compared to global breakpoint burden alone. Furthermore, Low Hscore may reflect a diffuse or untargeted instability, potentially linked to stochastic processes or generalized cellular constraints. In contrast, high Hscore indicates specific mechanistic processes such as transcription-replication collisions or transcription-associated stress. The intermediate Hscore likely reflects a convergence of transcription-associated GIN and cellular constraints such as clonal selection, leading to a state that is both permissive to genomic diversity and conducive to aggressive tumor behavior. These insights have direct clinical implications, as patients with high transcriptional stress (High iTRAC) may benefit from therapies targeting transcription-associated mechanisms, such as PARP inhibitors, while patients with low or diffuse instability might require alternative strategies. Indeed, Petropoulos *et al*. 2024 elegantly demonstrated that Transcription–replication conflicts underlie sensitivity to PARP inhibitors (Petropoulos *et al*. 2024). Future studies should aim to further elucidate the biological drivers of Hscore enrichment and validate its utility as

a biomarker for precision oncology. This work underscores the need to move beyond bulk measures of mutation load and instead focusing on the structural and functional contexts of genomic instability.

Acknowledgments

This work was supported by **Région Occitanie**, **INCa (Institut National du Cancer)**, **Inserm**, **Inserm Transfert**, **IUCT/ICR (Institut universitaire de cancerologie de Toulouse/Institut Claudius Regaud)**. We thank these institutions for their financial and strategic support of this research.

Ethics declaration

The samples used in this study are part of the Biological Resources Center of Bergonie Cancer Institute (CRB-IB). Accordance with the French Public Health Code (articles L. 1243-4 and R. 1243-61), the CRB-IB has received the agreement from the French authorities to delivered samples for scientific research (number AC-2008-812). The samples come from care and are re-qualified for research as part of the ICGC program (International Cancer Genome Consortium), with patient consent. The project was approved by the Bergonie Institute ethic committee (scientific advisory board).

Legends to figures

Figure 1: In each iTRAC stratification level, metastasis-free survival (MFS) outcomes differ between patients treated with chemotherapy and those untreated. A. Kaplan–Meier survival plot showing the panSTS cohort of iTRAC patients who were not treated with chemotherapy, stratified into Low, Medium, and High iTRAC levels. B. Hazard Ratio (HR) with a 95% confidence interval (CI) for the risk of metastasis in each ITRAC group relative to the Low group for the non-chemotherapy-treated panSTS cohort. P-values for each HR are displayed above each condition. The dashed horizontal line indicates an HR of 1. C, D, E. Kaplan–Meier plots for chemotherapy-treated and untreated patients in the Low, Medium, and High iTRAC groups, respectively. F. Kaplan–Meier plot of the chemotherapy-treated panSTS cohort stratified into Low, Medium, and High iTRAC levels. G. Hazard Ratio (HR) with a 95% confidence interval (CI) for the risk of metastasis in each iTRAC group relative to the Low group for the chemotherapy-treated panSTS cohort. P-values for each HR are shown above each condition. The dashed horizontal line indicates an HR of 1.

Figure 2: MFS stratification of chemotherapy-treated and not treated patients using FNCLCC and CINSARC. A. Kaplan-Meier plot for patients without chemotherapy stratified by FNCLCC. B. Kaplan-Meier plot for patients treated with chemotherapy stratified by FNCLCC. C Kaplan-Meier plot for patients without chemotherapy stratified by CINSARC A Kaplan-Meier plot for patients treated with chemotherapy stratified by CINSARC.

Figure 3. FNCLCC and CINSARC levels have similar MFS in between treated and not treated patients. A,B, Kaplan-Meier for patient with or without chemotherapy in FNCLCC grades 1-2, and 3 respectively. B,D, Kaplan-Meier for patient with or without chemotherapy in CINSARC groups C1, and C2,

Figure 4. MFS analysis using Multivariate cox regression using iTRAC FNCLCC and CINSARC as covariates in A. in PanSTS patients not treated with chemotherapy B. Treated with chemotherapy.

supplementary Figure 1 : Stratification of panDF cohort using iTRAC BP counts is more significant than using total BP count : A,B Kaplan Meier and Hazard ratio for stratification of panSTS cohort using iTRAC BP counts. CD, aplan Meier and Hazard ratio for stratification of panSTS cohort using total BP counts.

Figures



Figure 1


A
FNCLCC
chemotherapy No
Strata 1 (N=17, Events=6) 2 (N=49, Events=19) 3 (N=89, Events=39)
Metastasis Free Survival
p = 0.1
Time (years)
Number at risk
1 (N=17, Events=6) 17 8 2 0
2 (N=49, Events=19) 49 13 3 0
3 (N=89, Events=39) 89 16 3 0
Time (years)
B
FNCLCC
chemotherapy Yes
Strata 1 (N=1, Events=1) 2 (N=11, Events=5) 3 (N=47, Events=20)
Metastasis Free Survival
p = 0.83
Time (years)
Number at risk
1 (N=1, Events=1) 1 0 0 0 0
2 (N=11, Events=5) 11 3 0 0 0
3 (N=47, Events=20) 47 16 8 4 1
Time (years)
C
CINSARC
Chemotherapy No
Strata C1 (N=29, Events=6) C2 (N=86, Events=49)
Metastasis Free Survival
p = 0.003
Time (years)
Number at risk
C1 (N=29, Events=6) 29 13 3 1 0
C2 (N=86, Events=49) 86 24 5 1 0
Time (years)
D
CINSARC
Chemotherapy Yes
Strata C1 (N=18, Events=6) C2 (N=27, Events=17)
Metastasis Free Survival
p = 0.078
Time (years)
Number at risk
C1 (N=18, Events=6) 18 8 3 3 1
C2 (N=27, Events=17) 27 11 5 1 0
Time (years)

Figure 2


A
FNCLCCbis 1-2
Strata No (N=66, Events=25) Yes (N=12, Events=6)
Metastasis Free Survival
p = 0.67
Time (years)
Number at risk
Strata
No (N=66, Events=25) 66 21 5 0
Yes (N=12, Events=6) 12 3 0 0
B
FNCLCCbis 3
Strata No (N=89, Events=39) Yes (N=47, Events=20)
Metastasis Free Survival
p = 0.17
Time (years)
Number at risk
Strata
No (N=89, Events=39) 89 16 3 0 0
Yes (N=47, Events=20) 47 16 8 4 1
C
CINSARC C1
Strata No (N=29, Events=6) Yes (N=18, Events=6)
Metastasis Free Survival
p = 0.55
Time (years)
Number at risk
Strata
No (N=29, Events=6) 29 13 3 1 0
Yes (N=18, Events=6) 18 8 3 3 1
D
CINSARC C2
Strata No (N=86, Events=49) Yes (N=27, Events=17)
Metastasis Free Survival
p = 0.67
Time (years)
Number at risk
Strata
No (N=86, Events=49) 86 24 5 1 0
Yes (N=27, Events=17) 27 11 5 1 0
E
F

Figure 3

A


Endpoint Subgroup
HR CI p
MFS iTRAC.Levels:Medium 5.41 (2.39–12.21) <0.001
iTRAC.Levels:Low 1.58 (0.77–3.22) 0.211
FNCLCC:2 1.76 (0.59–5.27) 0.314
FNCLCC:3 1.52 (0.50–4.62) 0.456
CINSARC:C2 2.35 (0.96–5.75) 0.061
1 2 3 4 5 6 7 8 9 10

B


Endpoint Subgroup
HR CI p
MFS iTRAC.Levels:Medium 2.71 (0.87–8.43) 0.085
iTRAC.Levels:Low 4.89 (1.53–15.60) 0.007
FNCLCC:2 0.69 (0.07–6.82) 0.752
FNCLCC:3 0.72 (0.07–7.07) 0.780
CINSARC:C2 2.09 (0.75–5.84) 0.159
1 2 3 4 5 6 7 8 9 10

Figure 4



Supplementary figure 1

supplementary table 1 : panSTS cohort description

Characteristics	panSTS cohort (n=226)
Median follow-up (months)[IQR]	2.35[4.15]
Median age at diagnosis (years)[IQR]	64[17.75]
Female sex (%)	59.93(26.5)
FNCLCC grade (%)	
1 and 2	78(34.5)
3	136(60.2)
ND	12(5.3)
CINSARC (%)	
C1	43(20.8)
C2	113(50)
ND	66(29.2)
Histological type (%)	
Leimyosarcomas	122(54)
Undifferentiated pleomorphic sarcoma	45(19.9)
Liposarcoma - dedifferentiated	21(9.3)
Myxofibrosarcoma	18(8)
Liposarcoma - pleomorphic	8(3.5)
Pleomorphic rhabdomyosarcoma	5(2.2)
Endometrial stromal sarcoma	3(1.3)
Low grade fibromyxoid sarcoma	2(0.9)
Malignant solitary fibrous tumor	2(0.9)
Metastatic events(%)	
Yes	96(42.48)
No	130(57.52)
Therapeutic management(%)	
chemotherapy	59(26)
radiotherapy	113(50)
Radiotherapy lines (% radiotherapy)	57(22.62)
First	1(0.8)
Second	87(77)
Third	25(22.2)

Supplemental table 1 : STS patients characteristics

ND : Not Determined

IQR : InterQuartile Range

supplementary table 2 : panSTS patient's clinical data

Table legend :

META : 1 means presence of metastatic event, 0 no metastatic event

META_DATE : Time in year from diagnostic to first metastasis occurrence. Otherwise,time from diganostic to last fellowup

Chemotherapy : Yes patient treated with peri-operative chemotherapy, No

Radiotherapy : Indicates whether the patient received radiotherapy and, if so, the line of treatment in which it was administered (e.g., Second = second-line radiotherapy). "No" denotes no radiotherapy received.

Histotype : Histological subtype of soft tissue sarcoma as determined by pathological examination

Total.BP : Total number fusion transcripts BP computed as the sum of split-read coverage at each BP

iTRAC.BP : Number of BP at iTRAC genomic interval

iTRAC.size : The size, in base pairs, of iTRAC genomic interval

iTRAC.Levels : The iTRAC level of each patients based on stratification using the methode described in the paper

NGS :Type of next-generation sequencing (NGS) performed on the tumor sample. "mRNAseq" refers to messenger RNA sequencing targeting polyadenylated transcripts; "RNAseq" denotes total RNA sequencing, which may include both coding and non-coding RNA species.

Sex : Biological sex of the patient as recorded in clinical records; categorized as "Male" or "Female"

Age_at_diagnosis : Patient’s age in years at the time of initial diagnosis of soft tissue sarcoma, as recorded in the clinical file.

CINSARC : Patient’s clinical risk stratification using CINSARC signature

FNCLCC : Patient’s clinical risk stratification using FNCLCC grading

SAMPLE_ID	META	META_DATE	Chemotherapy	Chemotherapy.2	Radiotherapy	Histotype	Total.BP	ITRAC.BP	ITRAC.size	ITRAC.Hscore	ITRAC.Levels	NGS	Sex	Age_at_diagnosis	CINSARC	FNCLCC
LMS1T		0.5082819986307	No	No	No	Leiomyosarcoma	944	101	8633400	28.126697419511	High	RNAseq	Female	[60-69]	C2	3
LMS2T		0.19.76728268303 8	Adjuvant	Yes	Second	Leiomyosarcoma	4682	355	8633400	56.1923250219	High	RNAseq	Male	[50-59]	C2	3
LMS3T		0.6.22861054072553	No	No	No	Leiomyosarcoma	230	19	8633400	4.74373698771139	Low	RNAseq	Female	[50-59]	C1	1
LMS4T		0.9175844763860 4	Adjuvant	Yes	No	Leiomyosarcoma	570	66	8633400	20.7795079210399	Medium	RNAseq	Female	[60-69]	C1	2
LMS5T		1.8412046543434	No	No	No	Leiomyosarcoma	1672	43	8633400	0.105337732418501	Low	RNAseq	Female	[50-59]	C2	3
LMS6T		1.2862422997946	Neoadjuvant	Yes	No	Leiomyosarcoma	446	21	8633400	1.86873071116784	Low	RNAseq	Female	[60-69]	C2	3
LMS7T1		0.04308561259411	No	No	No	Leiomyosarcoma	360	7	8633400	0.0813783366306	Low	RNAseq	Female	[60-69]	C2	1
LMS8T1		0.9760438056129	No	No	No	Leiomyosarcoma	536	24	8633400	1.77239757084031	Low	RNAseq	Female	[60-69]	C2	3
LMS9T1		0.4608384835739 5	No	No	Second	Leiomyosarcoma	1866	195	8633400	51.1527634815103	High	RNAseq	Male	[60-69]	C1	2
LMS10T		1.6290212183436	No	No	No	Leiomyosarcoma	592	80	8633400	29.3908511484373	High	RNAseq	Female	[60-69]	C2	3
LMS11T		1.8324014442429	Adjuvant	Yes	Third	Leiomyosarcoma	80	8	8633400	2.04222076043721	Low	RNAseq	Female	[60-69]	C2	3
LMS12T		6.6310746064395	No	No	Second	Leiomyosarcoma	180	14	8633400	3.51892263501 92	Low	RNAseq	Female	[60-69]	C2	2
LMS13T		1.5322819301846	No	No	No	Leiomyosarcoma	172	7	8633400	0.871507636083836	Low	RNAseq	Male	[50-59]	C2	1
LMS14T		3.2288774811728	No	No	No	Leiomyosarcoma	348	10	8633400	0.354701002771289	Low	RNAseq	Female	[50-59]	C2	NA
LMS15T		0.8722108145106 1	No	No	Second	Leiomyosarcoma	1122	316	8633400	207.852139911048	High	RNAseq	Male	[40-49]	C2	3
LMS16T		1.6057648866258	Adjuvant	Yes	Second	Leiomyosarcoma	350	45	8633400	16.4137977466429	Medium	RNAseq	Male	[80-89]	C2	3
LMS18T1		1.5550992470910 3	No	No	Second	Leiomyosarcoma	2812	89	8633400	6.67482938872182	Low	RNAseq	Male	[60-69]	C2	2
LMS19T1		1.3689253935605	No	No	No	Leiomyosarcoma	488	35	8633400	7.19664315958406	Low	RNAseq	Female	[70-79]	NA	2
LMS20T		1.8590006844627	No	No	No	Leiomyosarcoma	106	0	8633400	0.0189780649977 68	Low	RNAseq	Female	[50-59]	C2	1
LMS21T		1.6050650239516 4	Adjuvant	Yes	No	Leiomyosarcoma	268	49	8633400	24.6088935649992	Medium	RNAseq	Female	[60-69]	C1	3
LMS22T		1.8076659822097	No	No	Second	Leiomyosarcoma	1096	17	8633400	0.00101639621268306	Low	RNAseq	Male	[60-69]	C2	3
LMS23T		6.0860422997946	No	No	No	Leiomyosarcoma	460	1	8633400	0.407018737241e-06	Low	RNAseq	Female	[70-79]	C2	NA
LMS25T		2.5462012320328 5	No	No	No	Leiomyosarcoma	122	2	8633400	0.156816936686641	Low	RNAseq	Male	[70-79]	C2	1
LMS27T		1.5092402464065 71	No	No	Second	Leiomyosarcoma	118	31	8633400	21.2692771411775	Medium	RNAseq	Female	[70-79]	C1	2
LMS28T		1.5779603116587	No	No	Second	Leiomyosarcoma	1484	215	8633400	81.5703572884971	High	RNAseq	Female	[50-59]	C2	NA
LMS30T		1.1211498973306	No	No	No	Leiomyosarcoma	1142	109	8633400	26.0444812599564	Medium	RNAseq	Female	[70-79]	C2	3
LMS31T		0.9566104038299	Adjuvant	Yes	No	Leiomyosarcoma	434	91	8633400	49.3798246862459	High	RNAseq	Female	[60-69]	C1	2
LMS32T		0.5462012320328 4	No	No	No	Leiomyosarcoma	398	28	8633400	5.03656101660411	Low	RNAseq	Female	[70-79]	C2	1
LMS33T		1.2209445585251	No	No	No	Leiomyosarcoma	954	0	8633400	0.0401200827198e-08	Low	RNAseq	Female	[70-79]	C2	2
LMS35T		1.2758394668056	No	No	Second	Leiomyosarcoma	832	93	8633400	27.4473372240603	Medium	RNAseq	Female	[70-79]	C2	3
LMS36T		0.1546885694726	No	No	Second	Leiomyosarcoma	614	37	8633400	7.24263358563443	Low	RNAseq	Female	[70-79]	C2	3
LMS37T		1.6714579055441 5	No	No	No	Leiomyosarcoma	164	68	8633400	60.7254881914004	High	RNAseq	Female	[60-69]	C2	2
LMS38T		0.5631750069130 7	No	No	No	Leiomyosarcoma	74	5	8633400	1.66897515789499	Low	RNAseq	Female	[60-69]	C1	1
LMS39T		1.4567770073919 7	No	No	Second	Leiomyosarcoma	372	38	8633400	10.9234371633388	Medium	RNAseq	Female	[60-69]	C2	3
LMS40T		0.7501711156742	No	No	Second	Leiomyosarcoma	448	79	8633400	37.3544023189928	High	RNAseq	Female	[50-59]	C2	3
LMS41T		1.3579739904175 2	No	No	Second	Leiomyosarcoma	184	38	8633400	23.4818707663382	Medium	RNAseq	Female	[50-59]	NA	3
LMS42T		1.8843258042367	No	No	Second	Leiomyosarcoma	1146	115	8633400	29.2945193268187	High	RNAseq	Female	[70-79]	C2	2
LMS43T		0.4614442162902 1	No	No	No	Leiomyosarcoma	376	11	8633400	3.73960071114567	Low	RNAseq	Female	[70-79]	C2	3
LMS44T		1.7029431895617	No	No	No	Leiomyosarcoma	768	191	8633400	115.677151102605	High	RNAseq	Female	[50-59]	C2	3
LMS45T		0.2888432580424	No	No	Second	Leiomyosarcoma	306	0	8633400	0.850992699801384e-05	Low	RNAseq	Male	[60-69]	NA	3
LMS46T		1.4076043805612 6	No	No	No	Leiomyosarcoma	354	5	8633400	0.923094524736375	Low	RNAseq	Female	[40-49]	C2	3
LMS47T		0.3805612594113 2	No	No	Second	Leiomyosarcoma	1138	48	8633400	2.23667389326607	Low	RNAseq	Female	[70-79]	C2	3
LMS48T		1.6851477159478 1	Adjuvant	Yes	Third	Leiomyosarcoma	1102	68	8633400	8.14230315861214	Low	RNAseq	Female	[70-79]	C1	1
LMS49T		0.5376454483207	No	No	No	Leiomyosarcoma	264	2	8633400	0.00692144882216784	Low	RNAseq	Female	[60-69]	C1	2
LMS50T		1.4161533196440 79	Adjuvant	Yes	No	Leiomyosarcoma	90	1	8633400	1.28275112510485	Low	RNAseq	Female	[60-69]	C1	2
LMS51T		0.1410609171800 1	No	No	No	Leiomyosarcoma	58	7	8633400	3.55043051887652	Low	RNAseq	Male	[60-69]	C1	2
LMS52T		0.2.56947296372 35	No	No	No	Leiomyosarcoma	870	12	8633400	0.500930470037594E-02	Low	RNAseq	Female	[60-69]	C2	2
LMS53T		0.9555099247091 03	No	No	Second	Leiomyosarcoma	1830	52	8633400	6.25711667973437	Low	RNAseq	Male	[60-69]	C2	2
LMS54T		1.4506502395619 4	No	No	No	Leiomyosarcoma	870	288	8633400	231.897946994847	High	RNAseq	Female	[30-39]	C2	2
LMS55T		1.4921286678987	Adjuvant	Yes	Third	Leiomyosarcoma	428	56	8633400	20.3986045894891	Medium	RNAseq	Female	[60-69]	C1	3
LMS57T		0.1505617935298	Palliative	Yes	Second	Leiomyosarcoma	120	8	8633400	2.04419294457602	Low	RNAseq	Female	[60-69]	C2	3
LMS58T		0.1369525393561	No	No	No	Leiomyosarcoma	222	3	8633400	0.0496289895131594	Low	RNAseq	Female	[70-79]	C2	2
LMS59T		1.5167693360718	Adjuvant	Yes	Third	Leiomyosarcoma	492	27	8633400	5.09433373911224	Low	RNAseq	Female	[50-59]	C2	3
LMS60T		2.1393018480428 1	Adjuvant	Yes	Third	Leiomyosarcoma	240	21	8633400	5.51818801465 6	Low	RNAseq	Female	[60-69]	C2	3
LMS61T		1.4893908281986	No	No	Second	Leiomyosarcoma	136	0	8633400	0.00767681533194444	Low	RNAseq	Female	[50-59]	C2	2
LMS62T		0.6.99794661190905	No	No	No	Leiomyosarcoma	426	119	8633400	79.2640340095221	High	RNAseq	Female	[60-69]	C1	2
LMS63T		0.2977412731006 2	No	No	Second	Leiomyosarcoma	82	3	8633400	0.657714245591777	Low	RNAseq	Female	[60-69]	C2	2
LMS64T		4.5612594113628	No	No	No	Leiomyosarcoma	34	2	8633400	1.14435695302461	Low	RNAseq	Male	[70-79]	C1	3
LMS65T		0.2306639288158	No	No	Second	Leiomyosarcoma	112	15	8633400	6.71146765772206	Low	RNAseq	Female	[20-29]	C1	3
LMS67T		0.3969883643415	No	No	No	Leiomyosarcoma	106	3	8633400	0.823894816658595	Low	RNAseq	Female	[60-69]	C1	2
LMS68T		0.2457221061451 1	No	No	Second	Leiomyosarcoma	140	3	8633400	0.229648291601895	Low	RNAseq	Female	[60-69]	NA	2
LMS69T		0.9370294318596	No	No	No	Leiomyosarcoma	554	38	8633400	5.14472816552721	Low	RNAseq	Female	[60-69]	C2	NA
LMS70T		1.6700889801505 8	No	No	No	Leiomyosarcoma	984	40	8633400	1.75815903117227	Low	RNAseq	Female	[40-49]	C2	NA
LMS71T		0.8172484599593	No	No	No	Leiomyosarcoma	328	105	8633400	77.0446331283	High	RNAseq	Female	[60-69]	C2	NA
LMS72T		1.0869247091053 4	No	No	No	Leiomyosarcoma	546	55	8633400	14.8920470149251	Medium	RNAseq	Female	[40-49]	C2	3
LMS73T		4.0383299110985	Adjuvant	Yes	No	Leiomyosarcoma	470	95	8633400	49.9643020931291	High	RNAseq	Female	[60-69]	C1	3
LMS74T		1.2173106616164	No	No	No	Leiomyosarcoma	574	37	8633400	5.37391933283 92	Low	RNAseq	Female	[60-69]	C2	NA
LMS76T		0.8186173853528	No	No	No	Leiomyosarcoma	1414	49	8633400	0.983218785468863	Low	RNAseq	Male	[80-89]	C2	3
LMS78T		1.0221769913757	No	No	No	Leiomyosarcoma	126	24	8633400	1.44761217192397	Low	RNAseq	Female	[20-29]	C2	2
LMS79T		1.2375088557837	No	No	No	Leiomyosarcoma	102	2	8633400	0.238403232007641	Low	RNAseq	Female	[40-49]	C2	2
LMS80T		0.3641341549859 9	No	No	No	Leiomyosarcoma	1280	414	8633400	298.796429219624	High	RNAseq	Female	[80-89]	NA	3
LMS81T		0.0636955030806 2	No	No	Second	Leiomyosarcoma	20	3	8633400	2.61077192104104	Low	RNAseq	Male	[50-59]	C1	2
LMS83T		1.6591375770205	No	No	No	Leiomyosarcoma	372	40	8633400	12.1428543005541	Medium	RNAseq	Male	[70-79]	C2	3
LMS84T		0.3073237508558	No	No	Second	Leiomyosarcoma	294	11	8633400	0.801076433923589	Low	RNAseq	Female	[50-59]	C2	2
LMS85T1		1.1053069171800 1	Adjuvant	Yes	No	Leiomyosarcoma	292	40	8633400	15.7382308529294	Medium	RNAseq	Female	[20-29]	C2	3
LMS86T		0.5235951938741	No	No	Second	Leiomyosarcoma	344	8	8633400	1.16783678238276E-02	Low	RNAseq	Female	[70-79]	C2	3
LMS87T1		0.8172484599593	No	No	No	Leiomyosarcoma	558	273	8633400	257.260551105532	High	RNAseq	Female	[60-69]	C2	2
LMS88T		0.2490759753934	No	No	No	Leiomyosarcoma	538	36	8633400	6.63071997587381	Low	RNAseq	Female	[70-79]	C2	3
LMS89T		0.7200547570157 43	No	No	No	Leiomyosarcoma	428	34	8633400	7.09866445246278	Low	RNAseq	Female	[70-79]	C2	1
LMS91T		0.1259411362068 77	No	No	No	Leiomyosarcoma	404	55	8633400	20.8923708575268	Medium	RNAseq	Female	[60-69]	C1	3
LMS95T1		0.4542498425738	No	No	No	Leiomyosarcoma	232	58	8633400	36.7401360874631	High	RNAseq	Female	[70-79]	C1	2
LMS96T1		0.1377138945927 45	No	No	No	Leiomyosarcoma	1146	81	8633400	12.3619083373174	Medium	RNAseq	Female	[70-79]	C2	3
LMS98T1		0.5366187542778 92	No	No	No	Leiomyosarcoma	292	39	8633400	15.0039573177755	Medium	RNAseq	Female	[80-89]	C2	3
LMS99T1		0.6680359206023	No	No	Second	Leiomyosarcoma	218	12	8633400	2.83033447723684	Low	RNAseq	Male	[80-89]	C1	3
N001		0.1319644079367	No	No	No	Undifferentiated pleomorphic sarcoma	140	13	8633400	4.15377802996506	Low	mRNAseq	Male	[60-69]	C2	2
N002		0.8514719947980 84	No	No	Second	Undifferentiated pleomorphic sarcoma	1632	78	8633400	4.78160884748413	Low	mRNAseq	Male	[70-79]	C1	2
N003		0.2387405886379 19	Neoadjuvant	Yes	No	Liposarcoma - dedifferentiated	9268	2005	8633400	350 High		mRNAseq	Male	[40-49]	NA	2
N004		1.8131416837823	Adjuvant	Yes	Second	Undifferentiated pleomorphic sarcoma	92	13	8633400	6.29788971805721	Low	mRNAseq	Male	[50-59]	C1	3
S925		0.2137097878165 6	Neoadjuvant	Yes	Third	Liposarcoma - pleomorphic	508	49	8633400	12.7065322600000	Medium	mRNAseq	Male	[40-49]	C1	3
N005		1.5182457221814 5	No	No	Second	Liposarcoma - dedifferentiated	8542	911	8633400	238.282074401577	High	mRNAseq	Male	[60-69]	C2	1
N007		1.4565366187542 8	Neoadjuvant adjuvant	Yes	Third	Undifferentiated pleomorphic sarcoma	620	36	8633400	4.9878464491294	Low	mRNAseq	Male	[60-69]	C2	1
N008		0.1519479808350 4	Neoadjuvant adjuvant	Yes	Third	Leiomyosarcoma	2584	588	8633400	350 High		mRNAseq	Male	[50-59]	C1	3
N009		0.2258726899384	No	No	Second	Liposarcoma - dedifferentiated	4350	919	8633400	350 High		mRNAseq	Male	[80-89]	C2	2
S901		0.8288842258042 4	No	No	No	Undifferentiated pleomorphic sarcoma	10998	2124	8633400	350 High		mRNAseq	Female	[60-69]	C2	2
S902		0.8120465434634	No	No	No	Liposarcoma - pleomorphic	2550	237	8633400	52.6492657383353	High	mRNAseq	Male	[50-59]	C1	NA
S814		1.2366723477075	Neoadjuvant	Yes	Third	Leiomyosarcoma	352	35	8633400	9.84571734541819	Medium	mRNAseq	Female	[70-79]	C2	2
S863		0.7636603696009 56	No	No	No	Undifferentiated pleomorphic sarcoma	338	31	8633400	8.02458702643 1	Low	mRNAseq	Female	[30-39]	C1	2
S919		1.8590006844627	No	No	Second	Liposarcoma	330	140	8633400	102.125939391122	High	mRNAseq	Female	[60-69]	NA	3
S815		0.7147905644147 8	No	No	Second	Leiomyosarcoma	842	192	8633400	108.862294904932	High	mRNAseq	Female	[60-69]	C2	3
S920		0.2525656735121 94	No	No	Second	Liposarcoma - dedifferentiated	6592	608	8633400	130.742924921 9	High	mRNAseq	Female	[40-49]	C1	3
S926		0.1408355920602 3	Adjuvant	Yes	Second	Undifferentiated pleomorphic sarcoma	342	135	8633400	112.683453385665	High	mRNAseq	Female	[50-59]	C2	3
S838		0.1287612518823	No	No	Second	Undifferentiated pleomorphic sarcoma	248	27	8633400	8.78490600066699	Low	mRNAseq	Female	[30-39]	NA	3
S816		1.2748802190280 3	No	No	No	Leiomyosarcoma	242	83	8633400	64.2117570906393	High	mRNAseq	Female	[40-49]	C2	2
S922		0.1287612518823	No	No	Second	Undifferentiated pleomorphic sarcoma	166	16	8633400	5.04280056853779	Low	mRNAseq	Female	[80-89]	NA	3
S924		0.4469541409932	Adjuvant	Yes	Second	Undifferentiated pleomorphic sarcoma	1144	338	8633400	229.748240576498	High	mRNAseq	Male	[40-49]	C2	2
S817		0.2113620807656 98	No	No	Second	Leiomyosarcoma	410	20	8633400	1.97476163703269	Low	mRNAseq	Female	[80-89]	C1	3
S818		0.1013073237508 6	No	No	Second	Myxofibrosarcoma	1600	168	8633400	44.5833909091837	High	mRNAseq	Female	[80-89]	C2	1
S819		1.1998631074604 3	No	No	No	Leiomyosarcoma	3078	356	8633400	104.313707194122	High	mRNAseq	Female	[60-69]	C2	NA
S820		0.8226839371738 9	Adjuvant	Yes	Second	Liposarcoma	398	33	8633400	7.37076252791231	Low	mRNAseq	Male	[60-69]	C1	3
S821		0.4223134839513	No	No	First	Liposarcoma - dedifferentiated	7428	637	8633400	122.482289966768	High	mRNAseq	Female	[60-69]	C1	2
S822		0.1634496919179	Adjuvant	Yes	Second	Undifferentiated pleomorphic sarcoma	1856	403	8633400	247.410254423465	High	mRNAseq	Male	[60-69]	C1	3
S823		1.8131416837823	No	No	Second	Myxofibrosarcoma	966	96	8633400	24.4931966514667	Medium	mRNAseq	Male	[60-69]	C2	2
S923		0.1971252566735	No	No	Second	Leiomyosarcoma	176	2	8633400	0.0486735877691011	Low	mRNAseq	Male	[30-39]	C1	1
S934		0.4517453798797	Neoadjuvant	Yes	No	Liposarcoma - dedifferentiated	4808	668	8633400	238.405488305209	High	mRNAseq	Male	[70-79]	NA	3
S927		0.3148528405201 92	No	No	Second	Liposarcoma - pleomorphic	564	49	8633400	11.0303489910547	Medium	mRNAseq	Female	[70-79]	C1	3
S824		0.0253251197807	Neoadjuvant adjuvant	Yes	No	Liposarcoma - dedifferentiated	9044	1512	8633400	350 High		mRNAseq	Female	[70-79]	C2	3
S825		0.7720739219712 53	Adjuvant	Yes	Third	Undifferentiated pleomorphic sarcoma	2020	298	8633400	114.347803481861	High	mRNAseq	Male	[60-69]	C2	3
S826		1.3695548254201	Adjuvant	Yes	No	Leiomyosarcoma	1568	302	8633400	143.136013815504	High	mRNAseq	Female	[40-49]	C2	3
S827		0.8008231553261	Adjuvant	Yes	Second	Myxofibrosarcoma	452	47	8633400	13.4553279196132	Medium	mRNAseq	Male	[40-49]	C2	3
S928		1.6182356392882	No	No	Second	Undifferentiated pleomorphic sarcoma	1508	363	8633400	242.462579908605	High	mRNAseq	Female	[60-69]	C2	NA
S828		0.2621492128679	Adjuvant	Yes	Third	Pleomorphic rhabdomyosarcoma	5542	33	8633400	0 Low		mRNAseq	Male	[50-59]	C1	2
S829		1.3233708555783 7	Adjuvant	Yes	Third	Pleomorphic rhabdomyosarcoma	1518	210	8633400	78.0364840437939	High	mRNAseq	Male	[60-69]	C2	3
S830		0.0082135523613963	No	No	Liposarcoma - dedifferentiated	11362	2615	8633400	350 High		mRNAseq	Female	[50-59]	C2	2
S831		0.8624229794661	No	No	Second	Undifferentiated pleomorphic sarcoma	1398	315	8633400	175.50003683392	High	mRNAseq	Male	[80-89]	C2	3
S917		0.9609895262638 98	No	No	Second	Liposarcoma - pleomorphic	814	21	8633400	3.68538684547243	Low	mRNAseq	Male	[60-69]	NA	3
S903		0.8071184120454 3	Adjuvant	Yes	Second	Low grade fibromyxoid sarcoma	122	40	8633400	31.1716374528 28	High	mRNAseq	Female	[20-29]	C1	3
S832		0.7832991101984	No	No	Second	Myxofibrosarcoma	22	3	8633400	2.45209575543135	High	mRNAseq	Female	[70-79]	C1	3
S918		0.4332648706365	Adjuvant	Yes	Second	Undifferentiated pleomorphic sarcoma	1094	136	8633400	44.5416868766608	High	mRNAseq	Female	[60-69]	C1	3
S921		0.7865845114305 3	No	No	No	Myxofibrosarcoma	954	284	8633400	194.452358419134	High	mRNAseq	Female	[80-89]	C2	2
S833		1.6047912388774 8	Neoadjuvant adjuvant	Yes	Third	Liposarcoma - pleomorphic	424	72	8633400	33.0973846518021	High	mRNAseq	Male	[60-69]	C2	3
M972		1.8179232926532	No	No	Second	Endometrial stromal sarcoma	586	5	8633400	0.000226765905143E-06	Low	mRNAseq	Female	[40-49]	NA	2
S905		0.5496235455167 7	Adjuvant	Yes	Second	Myxofibrosarcoma	958	238	8633400	143.465510868382	High	mRNAseq	Male	[60-69]	C2	3
S834		0.4777549625455	Neoadjuvant adjuvant	Yes	Third	Undifferentiated pleomorphic sarcoma	184	26	8633400	11.1006794677461	Medium	mRNAseq	Male	[60-69]	C2	3
S906		1.2359110198942	No	No	Second	Liposarcoma - dedifferentiated	10808	2388	8633400	350 High		mRNAseq	Male	[70-79]	C2	2
S907		0.7885578370788	Adjuvant	Yes	Third	Undifferentiated pleomorphic sarcoma	4662	722	8633400	287.539463166116	High	mRNAseq	Male	[50-59]	C1	3
S835		1.0249144421629 23	Adjuvant	Yes	No	Leiomyosarcoma	40	13	8633400	11.4108149867908	Low	mRNAseq	Male	[30-39]	C2	3
S908		1.8370978781656	No	No	Second	Liposarcoma - dedifferentiated	7272	279	8633400	5.31238867936917	Low	mRNAseq	Male	[80-89]	C1	2
S836		1.3402464065708 4	No	No	Second	Undifferentiated pleomorphic sarcoma	390	37	8633400	8.73589000773138	Medium	mRNAseq	Male	[40-49]	C2	3
S899		0.4907597535934	No	No	Second	Undifferentiated pleomorphic sarcoma	604	8	8633400	0.00337552126009286	Low	mRNAseq	Female	[60-69]	C1	3
S910		0.2868309771389 5	Adjuvant	Yes	Second	Liposarcoma - dedifferentiated	4716	632	8633400	237.222677097041	High	mRNAseq	Male	[40-49]	C1	3
S837		1.4811777258347	No	No	No	Myxofibrosarcoma	260	42	8633400	19.1928604355372	Medium	mRNAseq	Male	[60-69]	C2	2
S911		0.8145106061718	No	No	Second	Undifferentiated pleomorphic sarcoma	1574	83	8633400	6.65855704847705	Low	mRNAseq	Male	[80-89]	C1	NA
S839		1.0517180013689254	Adjuvant	Yes	Second	Undifferentiated pleomorphic sarcoma	972	94	8633400	23.0833809009682	Medium	mRNAseq	Female	[60-69]	C2	3
S900		1.4757051574242	Adjuvant	Yes	Third	Pleomorphic rhabdomyosarcoma	252	47	8633400	24.0727156178 9	Medium	mRNAseq	Male	[50-59]	C2	3
S840		0.4780387473265	Adjuvant	Yes	No	Malignant solitary fibrous tumor	574	217	8633400	174.747827172838	High	mRNAseq	Male	[50-59]	C1	3
S930		0.8295687885010 3	No	No	No	Malignant solitary fibrous tumor	874	423	8633400	350 High		mRNAseq	Male	[50-59]	C1	2
S912		0.9438056125941 1	No	No	Second	Leiomyosarcoma	66	3	8633400	0.891644872282 6	Low	mRNAseq	Female	[60-69]	C1	3
S914		1.0774817727585	No	No	No	Liposarcoma - pleomorphic	110	23	8633400	13.8342571566624	Medium	mRNAseq	Female	[70-79]	C2	3
S842		0.2179325026675	No	No	No	Liposarcoma - pleomorphic	1114	434	8633400	350 High		mRNAseq	Male	[70-79]	C2	3
S843		0.2271047227681	No	No	Second	Myxofibrosarcoma	1020	236	8633400	134.807253525337	High	mRNAseq	Male	[40-49]	C2	2
S929		1.1114355270382 7	No	No	Second	Leiomyosarcoma	2458	273	8633400	76.5793005382457	High	mRNAseq	Female	[40-49]	C2	3
S931		1.8699520876123	Adjuvant	Yes	No	Undifferentiated pleomorphic sarcoma	302	23	8633400	4.89232793567768	Low	mRNAseq	Female	[30-39]	C2	2
S844		0.1241820670734	No	No	Second	Undifferentiated pleomorphic sarcoma	1228	583	8633400	350 High		mRNAseq	Male	[30-39]	C2	3
S845		0.1581188829588	Adjuvant	Yes	Third	Pleomorphic rhabdomyosarcoma	94	27	8633400	19.9329737327 57	Medium	mRNAseq	Male	[30-39]	C2	3
S932		0.2518822724615 3	No	No	No	Myxofibrosarcoma	776	58	8633400	10.1456497449 79	Medium	mRNAseq	Male	[80-89]	C2	3
S846		1.6720054757057 4	No	No	Second	Liposarcoma	210	56	8633400	33.5743002632 7	High	mRNAseq	Male	[50-59]	C2	3
S933		1.4182067073443	No	No	Second	Undifferentiated pleomorphic sarcoma	736	56	8633400	10.1332767307208	Medium	mRNAseq	Female	[60-69]	C2	2
S935		1.4544832306639	No	No	No	Undifferentiated pleomorphic sarcoma	586	70	8633400	22.7273848807123	Medium	mRNAseq	Male	[60-69]	C2	3
S847		1.3826146475017	No	No	No	Leiomyosarcoma	280	65	8633400	38.7518833841784	High	mRNAseq	Female	[60-69]	C2	3
S936		1.4366875005457	No	No	No	Myxofibrosarcoma	1188	141	8633400	43.7267904561	High	mRNAseq	Male	[60-69]	C2	3
S848		0.3778234086243	No	No	Second	Undifferentiated pleomorphic sarcoma	640	71	8633400	21.1505483637 5	Medium	mRNAseq	Male	[40-49]	C2	3
S937		0.9884941820677	Neoadjuvant	Yes	Third	Leiomyosarcoma	6514	1304	8633400	350 High		mRNAseq	Female	[60-69]	C2	2
S849		1.2183436002737 9	No	No	No	Undifferentiated pleomorphic sarcoma	310	9	8633400	3.27961811875388	Low	mRNAseq	Female	[70-79]	C2	3
S850		1.2402440657084	No	No	Second	Myxofibrosarcoma	526	14	8633400	0.238093408021 1	Low	mRNAseq	Male	[70-79]	C2	3
S851		1.2614647501712	No	No	Second	Undifferentiated pleomorphic sarcoma	460	24	8633400	2.56558725165533	Low	mRNAseq	Male	[40-49]	C2	3
S913		0.3121149897306	No	No	Second	Leiomyosarcoma	412	42	8633400	11.8917137313672	Medium	mRNAseq	Female	[60-69]	C1	3
S853		0.8865947298374	Adjuvant	Yes	Third	Undifferentiated pleomorphic sarcoma	372	4	8633400	0.924656974827464E-02	Low	mRNAseq	Male	[50-59]	C2	3
S855		0.2758384668056	No	No	Second	Undifferentiated pleomorphic sarcoma	108	9	8633400	2.87779315256	Low	mRNAseq	Male	[70-79]	C2	3
S973		1.3370294318596 2	No	No	No	Myxofibrosarcoma	430	59	8633400	22.4074715253 18	Medium	mRNAseq	Male	[60-69]	C2	3
S856		0.7590691307237	No	No	No	Leiomyosarcoma	644	87	8633400	31.7963303301884	High	mRNAseq	Male	[70-79]	C2	3
S857		1.2445959958224	No	No	No	Leiomyosarcoma	1058	248	8633400	97.5779431035298	High	mRNAseq	Female	[70-79]	C2	2
S858		0.4542498425738	Adjuvant	Yes	Third	Undifferentiated pleomorphic sarcoma	626	65	8633400	17.9853558580398	Medium	mRNAseq	Male	[30-39]	NA	3
S915		0.4089664613278	No	No	No	Leiomyosarcoma	640	28	8633400	1.81255433658857	Low	mRNAseq	Female	[60-69]	NA	2
S859		1.4182067073443	No	No	Second	Undifferentiated pleomorphic sarcoma	1312	106	8633400	19.8303669661352	Medium	mR

Bibliography

Aguilera, Andrés, et Belén Gómez-González. 2008. « Genome Instability: A Mechanistic View of Its Causes and Consequences ». *Nature Reviews Genetics* 9 (3): 204-17. https://doi.org/10.1038/nrg2268.

Anders, Simon, Paul Theodor Pyl, et Wolfgang Huber. 2015. « HTSeq—a Python Framework to Work with High-Throughput Sequencing Data ». *Bioinformatics* 31 (2): 166-69. https://doi.org/10.1093/bioinformatics/btu638.

Andor, Noemi, Trevor A Graham, Marnix Jansen, Li C Xia, C Athena Aktipis, Claudia Petritsch, Hanlee P Ji, et Carlo C Maley. 2016. « Pan-Cancer Analysis of the Extent and Consequences of Intratumor Heterogeneity ». *Nature Medicine* 22 (1): 105-13. https://doi.org/10.1038/nm.3984.

Baker, Darren J., Fang Jin, Karthik B. Jeganathan, et Jan M. Van Deursen. 2009. « Whole Chromosome Instability Caused by Bub1 Insufficiency Drives Tumorigenesis through Tumor Suppressor Gene Loss of Heterozygosity ». *Cancer Cell* 16 (6): 475-86. https://doi.org/10.1016/j.ccr.2009.10.023.

Bakhoum, Samuel F., Lilian Kabeche, Matthew D. Wood, Christopher D. Laucius, Dian Qu, Ashley M. Laughney, Gloria E. Reynolds, et al. 2015. « Numerical Chromosomal Instability Mediates Susceptibility to Radiation Treatment ». *Nature Communications* 6 (1): 5990. https://doi.org/10.1038/ncomms6990.

Benhaddou, Ataaillah, Laetitia Gaston, Gaëlle Pérot, Nelly Desplat, Laura Leroy, Sophie Le Guellec, Mohamed Ben Haddou, et al. 2021. « Medium Levels of Transcription and Replication Related Chromosomal Instability Are Associated with Poor Clinical Outcome ». *Scientific Reports* 11 (1): 23429. https://doi.org/10.1038/s41598-021-02787-x.

Birkbak, Nicolai J., Aron C. Eklund, Qiyuan Li, Sarah E. McClelland, David Endesfelder, Patrick Tan, Iain B. Tan, Andrea L. Richardson, Zoltan Szallasi, et Charles Swanton. 2011. « Paradoxical Relationship between Chromosomal Instability and Survival Outcome in Cancer ». *Cancer Research* 71 (10): 3447-52. https://doi.org/10.1158/0008-5472.CAN-10-3667.

Byrd-Leifer, Cynthia A., Ellen F. Block, Kiyoshi Takeda, Shizuo Akira, et Aihao Ding. 2001. « The Role of MyD88 and TLR4 in the LPS-Mimetic Activity of Taxol ». *European Journal of Immunology* 31 (8): 2448-57. https://doi.org/10.1002/1521-4141(200108)31:8<2448::AID-IMMU2448>3.0.CO;2-N.

Cahill, Daniel P, Kenneth W Kinzler, Bert Vogelstein, et Christoph Lengauer. 1999. « Genetic Instability and Darwinian Selection in Tumours ». *Trends in Genetics* 15 (12): M57-60. https://doi.org/10.1016/S0168-9525(99)01874-0.

Carter, Scott L, Aron C Eklund, Isaac S Kohane, Lyndsay N Harris, et Zoltan Szallasi. 2006. « A Signature of Chromosomal Instability Inferred from Gene Expression Profiles Predicts Clinical Outcome in Multiple Human Cancers ». *Nature Genetics* 38 (9): 1043-48. https://doi.org/10.1038/ng1861.

Chibon, Frédéric, Pauline Lagarde, Sébastien Salas, Gaëlle Pérot, Véronique Brouste, Franck Tirode, Carlo Lucchesi, et al. 2010. « Validated Prediction of Clinical Outcome in Sarcomas and Multiple Types of Cancer on the Basis of a Gene Expression Signature Related to Genome Complexity ». *Nature Medicine* 16 (7): 781-87. https://doi.org/10.1038/nm.2174.

Coindre, Jean-Michel, Philippe Terrier, Louis Guillou, Viviane Le Doussal, Françoise Collin, Dominique Ranchère, Xavier Sastre, Marie-Odile Vilain, Françoise Bonichon, et Binh N'Guyen Bui. 2001. « Predictive Value of Grade for Metastasis Development in the Main Histologic Types of Adult Soft Tissue Sarcomas: A Study of 1240 Patients from the French Federation of Cancer Centers Sarcoma Group ». *Cancer* 91 (10): 1914-26. https://doi.org/10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3.

Daenen, L G M, J M Houthuijzen, G A Cirkel, J M L Roodhart, Y Shaked, et E E Voest. 2014. « Treatment-Induced Host-Mediated Mechanisms Reducing the Efficacy of Antitumor Therapies ». *Oncogene* 33 (11): 1341-47. https://doi.org/10.1038/onc.2013.94.

Dobin, Alexander, Carrie A. Davis, Felix Schlesinger, Jorg Drenkow, Chris Zaleski, Sonali Jha, Philippe Batut, Mark Chaisson, et Thomas R. Gingeras. 2013. « STAR: Ultrafast Universal RNA-Seq Aligner ». *Bioinformatics* 29 (1): 15-21. https://doi.org/10.1093/bioinformatics/bts635.

Filleron, Thomas, Sophie Le Guellec, Christine Chevreau, Bastien Cabarrou, Tom Lesluyes, Sabrina Lodin, Angélique Massoubre, et al. 2020. « Value of Peri-Operative Chemotherapy in

Patients with CINSARC High-Risk Localized Grade 1 or 2 Soft Tissue Sarcoma: Study Protocol of the Target Selection Phase III CHIC-STS Trial ». *BMC Cancer* 20 (1): 716. https://doi.org/10.1186/s12885-020-07207-3.

Florl, Andrea R., et Wolfgang A. Schulz. 2008. « Chromosomal Instability in Bladder Cancer ». *Archives of Toxicology* 82 (3): 173-82. https://doi.org/10.1007/s00204-008-0280-3.

Janssen, Aniek, Geert J. P. L. Kops, et René H. Medema. 2009. « Elevating the Frequency of Chromosome Mis-Segregation as a Strategy to Kill Tumor Cells ». *Proceedings of the National Academy of Sciences* 106 (45): 19108-13. https://doi.org/10.1073/pnas.0904343106.

Karagiannis, George S., John S. Condeelis, et Maja H. Oktay. 2018. « Chemotherapy-Induced Metastasis: Mechanisms and Translational Opportunities ». *Clinical & Experimental Metastasis* 35 (4): 269-84. https://doi.org/10.1007/s10585-017-9870-x.

Kim, Jung-Hyun, Hee-Sheung Lee, Nicholas C. O. Lee, Nikolay V. Goncharov, Vadim Kumeiko, Hiroshi Masumoto, William C. Earnshaw, Natalay Kouprina, et Vladimir Larionov. 2016. « Development of a Novel HAC-Based “Gain of Signal” Quantitative Assay for Measuring Chromosome Instability (CIN) in Cancer Cells ». *Oncotarget* 7 (12): 14841-56. https://doi.org/10.18632/oncotarget.7854.

Komarova, Natalia L., et Dominik Wodarz. 2004. « The Optimal Rate of Chromosome Loss for the Inactivation of Tumor Suppressor Genes in Cancer ». *Proceedings of the National Academy of Sciences* 101 (18): 7017-21. https://doi.org/10.1073/pnas.0401943101.

Kuhn, R. M., D. Haussler, et W. J. Kent. 2013. « The UCSC Genome Browser and Associated Tools ». *Briefings in Bioinformatics* 14 (2): 144-61. https://doi.org/10.1093/bib/bbs038.

Lesluyes, Tom, Gaëlle Pérot, Marine Roxane Largeau, Céline Brulard, Pauline Lagarde, Valérie Dapremont, Carlo Lucchesi, et al. 2016. « RNA Sequencing Validation of the Complexity INdex in SARComas Prognostic Signature ». *European Journal of Cancer* 57 (avril):104-11. https://doi.org/10.1016/j.ejca.2015.12.027.

Li, Heng, Bob Handsaker, Alec Wysoker, Tim Fennell, Jue Ruan, Nils Homer, Gabor Marth, Goncalo Abecasis, Richard Durbin, et 1000 Genome Project Data Processing Subgroup. 2009. « The Sequence Alignment/Map Format and SAMtools ». *Bioinformatics* 25 (16): 2078-79. https://doi.org/10.1093/bioinformatics/btp352.

Ma, Yan, Ranjana Ambannavar, James Stephans, Jennie Jeong, Andrew Dei Rossi, Mei-Lan Liu, Adam J. Friedman, et al. 2014. « Fusion Transcript Discovery in Formalin-Fixed Paraffin-Embedded Human Breast Cancer Tissues Reveals a Link to Tumor Progression ». Édité par Shannon M. Hawkins. *PLoS ONE* 9 (4): e94202. https://doi.org/10.1371/journal.pone.0094202.

M'kacher, R., L. Andreoletti, S. Flamant, F. Milliat, T. Girinsky, J. Dossou, D. Violot, et al. 2010. « JC Human Polyomavirus Is Associated to Chromosomal Instability in Peripheral Blood Lymphocytes of Hodgkin's Lymphoma Patients and Poor Clinical Outcome ». *Annals of Oncology* 21 (4): 826-32. https://doi.org/10.1093/annonc/mdp375.

Nilsson, M. 2002. « Optimal Mutation Rates in Dynamic Environments ». *Bulletin of Mathematical Biology* 64 (6): 1033-43. https://doi.org/10.1006/bulm.2002.0314.

Petropoulos, Michalis, Angeliki Karamichali, Giacomo G. Rossetti, Alena Freudenmann, Luca G. Iacovino, Vasilis S. Dionellis, Sotirios K. Sotiriou, et Thanos D. Halazonetis. 2024. « Transcription–Replication Conflicts Underlie Sensitivity to PARP Inhibitors ». *Nature* 628 (8007): 433-41. https://doi.org/10.1038/s41586-024-07217-2.

Rossi, Lea, Denise Stevens, Jean-Yves Pierga, Florence Lerebours, Fabien Reyal, Mathieu Robain, Bernard Asselain, et Roman Rouzier. 2015. « Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population ». Édité par Tone Frost Bathen. *PLOS ONE* 10 (7): e0132853. https://doi.org/10.1371/journal.pone.0132853.

Roylance, Rebecca, David Endesfelder, Patricia Gorman, Rebecca A. Burrell, Jil Sander, Ian Tomlinson, Andrew M. Hanby, et al. 2011. « Relationship of Extreme Chromosomal Instability with Long-Term Survival in a Retrospective Analysis of Primary Breast Cancer ». *Cancer Epidemiology, Biomarkers & Prevention* 20 (10): 2183-94. https://doi.org/10.1158/1055-9965.EPI-11-0343.

Schvartzman, Juan-Manuel, Rocio Sotillo, et Robert Benezra. 2010. « Mitotic Chromosomal Instability and Cancer: Mouse Modelling of the Human Disease ». *Nature Reviews Cancer* 10 (2): 102-15. https://doi.org/10.1038/nrc2781.

Thompson, Ea, Yw Asmann, X Su, Mj Ellis, J Shao, Y Hu, Kp White, et al. 2016. « Abstract S4-02: A Comprehensive Analysis of Fusion Transcripts in Breast Cancer Reveals Associations between Number of Fusion Transcripts, Copy Number Events, Gene Expression Profiles, and Potentially

Clinical Outcome ». *Cancer Research* 76 (4_Supplement): S4-02-S4-02. https://doi.org/10.1158/1538-7445.SABCS15-S4-02.

Trapnell, Cole, Adam Roberts, Loyal Goff, Geo Pertea, Daehwan Kim, David R Kelley, Harold Pimentel, Steven L Salzberg, John L Rinn, et Lior Pachter. 2012. « Differential Gene and Transcript Expression Analysis of RNA-Seq Experiments with TopHat and Cufflinks ». *Nature Protocols* 7 (3): 562-78. https://doi.org/10.1038/nprot.2012.016.

Uhrig, Sebastian, Julia Ellermann, Tatjana Walther, Pauline Burkhardt, Martina Fröhlich, Barbara Hutter, Umut H. Toprak, et al. 2021. « Accurate and Efficient Detection of Gene Fusions from RNA Sequencing Data ». *Genome Research* 31 (3): 448-60. https://doi.org/10.1101/gr.257246.119.

Von Minckwitz, Gunter, Michael Untch, Jens-Uwe Blohmer, Serban D. Costa, Holger Eidtmann, Peter A. Fasching, Bernd Gerber, et al. 2012. « Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes ». *Journal of Clinical Oncology* 30 (15): 1796-1804. https://doi.org/10.1200/JCO.2011.38.8595.

Walther, A, R Houlston, et I Tomlinson. 2008. « Association between Chromosomal Instability and Prognosis in Colorectal Cancer: A Meta-Analysis ». *Gut* 57 (7): 941-50. https://doi.org/10.1136/gut.2007.135004.

Weaver, Beth A., et Don W. Cleveland. 2008. « The Aneuploidy Paradox in Cell Growth and Tumorigenesis ». *Cancer Cell* 14 (6): 431-33. https://doi.org/10.1016/j.ccr.2008.11.011.

Williams, Bret R., Vineet R. Prabhu, Karen E. Hunter, Christina M. Glazier, Charles A. Whittaker, David E. Housman, et Angelika Amon. 2008. « Aneuploidy Affects Proliferation and Spontaneous Immortalization in Mammalian Cells ». *Science* 322 (5902): 703-9. https://doi.org/10.1126/science.1160058.

Yamamoto, Yoshiaki, Hideyasu Matsuyama, Yasuyo Chochi, Masaru Okuda, Shigeto Kawauchi, Ryo Inoue, Tomoko Furuya, Atsunori Oga, Katsusuke Naito, et Kohsuke Sasaki. 2007. « Overexpression of BUBR1 Is Associated with Chromosomal Instability in Bladder Cancer ». *Cancer Genetics and Cytogenetics* 174 (1): 42-47. https://doi.org/10.1016/j.cancergencyto.2006.11.012.

Zaki, Bassem I., Arief A. Suriawinata, Alan R. Eastman, Kristen M. Garner, et Samuel F. Bakhoum. 2014. « Chromosomal Instability Portends Superior Response of Rectal Adenocarcinoma to Chemoradiation Therapy ». *Cancer* 120 (11): 1733-42. https://doi.org/10.1002/cncr.28656.

Zasadil, Lauren M., Kristen A. Andersen, Dabin Yeum, Gabrielle B. Rocque, Lee G. Wilke, Amye J. Tevaarwerk, Ronald T. Raines, Mark E. Burkard, et Beth A. Weaver. 2014. « Cytotoxicity of Paclitaxel in Breast Cancer Is Due to Chromosome Missegregation on Multipolar Spindles ». *Science Translational Medicine* 6 (229). https://doi.org/10.1126/scitranslmed.3007965.